RTTNews BiotechDoubao · 实盘不做把握 6/10不做原因:风险收益比不佳
北京时间·🕒 发布 00:29:22·⟳ 抓取 00:30:21 +59s·⚡ 决策 10-20 01:33:22 +1h03m·7.8 天前
Actinium（ATNM）EANM 2026 公布 ATNM-400 首个人体 I 期显像数据，股价盘中已涨约17%-21%
名义利好但属于典型的已预告会议+早期非疗效数据：会议安排10月15日即由公司预告，10月15-16日股价已累计涨约16%，报告结束后盘中再涨约17%-21%（$1.32，曾见$1.37），成交额较20日均量放大约1.6倍而公司市值仅约4,150万美元；披露内容仅为 Zr-89 显像剂的安全性/生物分布/剂量学与临床前模型，无治疗性疗效、MTD 或商业化里程碑，新增基本面增量不足以支撑在+20%位置追入。无实质性利空，不做空。
📄 原文RTTNews Biotech↗ 原文
Actinium Brings ATNM-400's Next-Generation Radiotherapy Approach To EANM 2026
Actinium Pharmaceuticals, Inc. (ATNM), a biotechnology company developing targeted radiotherapies for cancer, announced…
不做 Actinium Pharmaceuticals, Inc.（ATNM.US）
已提前预告的会议数据，落地内容仅为 I 期 Zr-89 显像剂安全性/生物分布/剂量学及临床前数据，无疗效或注册增量；股价会前两日累涨约16%、报告日盘中再涨约17%-21%，约4,000万美元微盘、成交极薄，追多风险收益比不足（sell-the-news 风险高）；无实质利空不做空。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
ATNM-400 的 EANM I 期数据本质是微剂量显像/生物分布读数而非疗效证据，且会议10月15日已预告、股价两个交易日提前拉升后今日再涨约20%，典型 sell-the-news 结构；4,000万美元微盘、流动性极薄，追多风险收益比不足，亦无做空催化，回避。
消息传播链
- 节点
- 节点
关键理由
- 数据处于 I 期显像 tracer（Zr-89）安全性/生物分布/剂量学阶段，不构成疗效或注册路径上的关键重定价事件
- 会议预告（10月15日）与会议日通稿（10月19日）均提前公开，10月15-16日已累涨约16%、报告落地后再涨约17%-21%，短期定价已较充分
主要风险
- 微盘股（市值约4,150万美元）+ 当日成交额仅约60万美元、买卖盘价差大，波动与滑点极高，若口头报告含未被报道的定量亮点可能继续逼空，反之易见光死
- 数据全文/幻灯尚未在公开渠道披露，若后续公司发布疗效相关正式通稿，本判断需重估
反向证据
- 做多前查反向 · 来源 web · 日期 2026-10-19 · 影响 weakens
未检索到任何疗效（ORR/PFS）、MTD 或注册进展 readout；公司与媒体通稿均只覆盖显像/剂量学与临床前数据，缺乏可重定价的疗效 surprise。
检索:Actinium ATNM-400 EANM 2026 efficacy results OR press release efficacy MTD 原文 ↗ - 做多前查反向 · 来源 futu行情 · 日期 2026-10-19 · 影响 weakens
10月15日+8.8%、10月16日+6.6%已提前反应会议预告，10月19日盘中再涨约17%-21%；市值约4,150万美元、当日成交约60万美元，量比1.56，追高承接与见光死风险均高。
检索:ATNM stock October 15 16 2026 run-up EANM presentation rally
先例如何影响了这次决策
对本次决策的影响:先例不足进一步压低置信度并支持回避：不追多、不做空。
方向:未取得可对齐的同市场、同相位、首发锚点可靠的微盘放疗公司会议数据先例，不以记忆臆造涨幅分布。
涨幅量级:无高相似 aligned 先例校准幅度；本次回避主要依据数据阶段（显像/剂量学而非疗效）与已实现的提前+当日累计涨幅，而非先例中位涨幅。
形态:无法用先例验证见光死概率，但会议提前预告→会前两日连涨→报告日盘中+20%、低市值低流动性本身是典型 sell-the-news 价格结构。
工具执行结果 · 成功 4 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 12 ms
{"result": "search_processed_events:agent query=`actinium atnm eanm october 2026 zirconium-89 biodistribution dosimetry | actinium pharmaceuticals atnm-400 eanm 2026 presentation | atnm-400 phase 1 dose escalation mcrpc her3 acti`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agen - stock_quote 成功 stock_tools HTTP · 923 ms
{ - web_search 成功 doubao_search · 2,150 ms
豆包搜索结果（原始查询:Actinium Pharmaceuticals ATNM-400 EANM 2026 Phase 1 data mCRPC results；API SearchType:web） - web_search 成功 doubao_search · 1,811 ms
豆包搜索结果（原始查询:Actinium ATNM-400 EANM data readout October 19 2026 tumor uptake dosimetry results announcement；API SearchType:web）
原文全文
展开原文 · 2,252 字
Actinium Pharmaceuticals, Inc. (ATNM), a biotechnology company developing targeted radiotherapies for cancer, announced that it will present clinical and preclinical data on its investigational drug candidate ATNM-400 at the 39th Annual Congress of the European Association of Nuclear Medicine (EANM), held October 17-21 in Vienna, Austria.
The clinical presentation will feature early data from the ongoing first-in-human Phase 1 dose-escalation study of ATNM-400 in metastatic castration-resistant prostate cancer (mCRPC).
The study evaluates the safety, biodistribution and dosimetry of its zirconium-89-labeled imaging counterpart, including tumor uptake and clearance assessed through serial PET scans.
A separate preclinical presentation will cover ATNM-400 studies in KRAS- and ALK-driven non-small cell lung cancer (NSCLC) models, evaluating the candidate alone and in combination with KRAS or ALK inhibitors.
Both presentations are scheduled for October 19, 2026, from 4:45 p.m. to 6:15 p.m. CEST. The clinical study will be presented in Session 1111 (OP-525), while the preclinical lung cancer research will be featured in Session 1109 (EPS-149).
ATNM-400 is an investigational, first-in-class actinium-225 antibody radio conjugate targeting HER3, an antigen distinct from PSMA. Actinium is exploring its potential in multiple solid tumors, including prostate and lung cancers, as a monotherapy and in combination with established treatments.
Actinium's pipeline includes targeted radiotherapies for solid tumors and blood cancers, as well as conditioning agents for bone marrow transplantation and cell and gene therapies. Its programs include ATNM-400, Actimab-A, Iomab-B and Iomab-ACT. ATNM-400 remains investigational and has not been approved for commercial use.
Currently, ATNM is trading at $1.37, up 21.24%.
For comments and feedback contact: editorial@rttnews.com
Business News
October 16, 2026 16:06 ET Monthly consumer price inflation data and retail sales figures were the main news from the U.S. economy this week. In Europe, monthly GDP figures from the U.K. gained attention. External trade data from China was in focus in Asia. Elsewhere, the International Monetary Fund released its latest projections for the global economy.
The clinical presentation will feature early data from the ongoing first-in-human Phase 1 dose-escalation study of ATNM-400 in metastatic castration-resistant prostate cancer (mCRPC).
The study evaluates the safety, biodistribution and dosimetry of its zirconium-89-labeled imaging counterpart, including tumor uptake and clearance assessed through serial PET scans.
A separate preclinical presentation will cover ATNM-400 studies in KRAS- and ALK-driven non-small cell lung cancer (NSCLC) models, evaluating the candidate alone and in combination with KRAS or ALK inhibitors.
Both presentations are scheduled for October 19, 2026, from 4:45 p.m. to 6:15 p.m. CEST. The clinical study will be presented in Session 1111 (OP-525), while the preclinical lung cancer research will be featured in Session 1109 (EPS-149).
ATNM-400 is an investigational, first-in-class actinium-225 antibody radio conjugate targeting HER3, an antigen distinct from PSMA. Actinium is exploring its potential in multiple solid tumors, including prostate and lung cancers, as a monotherapy and in combination with established treatments.
Actinium's pipeline includes targeted radiotherapies for solid tumors and blood cancers, as well as conditioning agents for bone marrow transplantation and cell and gene therapies. Its programs include ATNM-400, Actimab-A, Iomab-B and Iomab-ACT. ATNM-400 remains investigational and has not been approved for commercial use.
Currently, ATNM is trading at $1.37, up 21.24%.
For comments and feedback contact: editorial@rttnews.com
Business News
October 16, 2026 16:06 ET Monthly consumer price inflation data and retail sales figures were the main news from the U.S. economy this week. In Europe, monthly GDP figures from the U.K. gained attention. External trade data from China was in focus in Asia. Elsewhere, the International Monetary Fund released its latest projections for the global economy.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
6657e9fc74· 2026-10-20 01:33 · doubao / doubao-seed-evolving-latest-version · 策略包658c0c1e2ba5当前